Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 15th World Cardiac Surgery & Angiology Conference Philadelphia, Pennsylvania, USA.

Day 2 :

Keynote Forum

Nanette K Wenger

Emory University School of Medicine, USA

Keynote: Transforming CVD prevention for women: Time for the Pygmalion construct to end

Time : 9:00 AM

Cardiac Surgery 2016 International Conference Keynote Speaker Nanette K Wenger photo
Biography:

Wenger is Professor of Medicine in the Division of Cardiology at the Emory University School of Medicine and a consultant to the Emory Heart and Vascular Center.Coronary heart disease in women is one of Dr. Wenger’s major clinical and research interests. She chaired the U.S. National Heart, Lung, and Blood Institute Conference on Cardiovascular Health and Disease in Women. Dr. Wenger has expertise in cardiac rehabilitation. She chaired the World Health Organization Expert Committee on Rehabilitation after Cardiovascular Disease, and co-chaired the Guideline Panel on Cardiac Rehabilitation for the U.S. Agency for Health Care Policy and Research. Dr. Wenger has had a longstanding interest in geriatric cardiology, is a Past President of the Society of Geriatric Cardiology and was Editor-in-Chief of the American Journal of Geriatric Cardiology for more than 15 years

Abstract:

Gender-specific atherosclerotic cardiovascular disease (ASCVD) risk assessment for women is requisite owing to a number of non-traditional ASCVD risk factors that are unique to or predominant in women and because many traditional ASCVD risk factors impart differential risk for women and for men. Cardiovascular disease remains the leading cause of morbidity and mortality for women in the US and 2 of 3 US women have at least one major traditional coronary risk factor.

Non-traditional ASCVD risk factors requiring assessment for all women include a history of complications of pregnancy, use of oral contraceptive therapy,  therapy hormonal fertility, and menopausal hormone therapy. Systemic autoimmune disorders are highly prevalent in women and impart increased ASCVD risk.

Hypertension increases the population-adjusted CVD mortality more for women than for men, and cigeratte smoking imparts a greater CVD risk for women than men, as does diabetes mellitus. Hypercholesterolemia imparts the highest population-adjusted CVD risk for women, 47%. Two of three US women are obese or overweight, and obesity is double in women compared with men in low and middle0income nations. Physical inactivity is the most prevalent risk factor of US women. Psychosocial issues, particularly depression, preferentially disadvantage women.

Gender-specific risk assessment and intervention have the potential to improve CVD outcomes in women.